- Home
- MITQ vs PPCB Comparison
MITQ vs PPCB Comparison
Compare MITQ & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MITQ | PPCB |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MITQ | PPCB |
|---|---|---|
| Price | $0.73 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.6K | ★ 565.5K |
| Earning Date | 02-12-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,477,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.24 |
| 52 Week High | $1.66 | $145.46 |
Technical Indicators
Market Signals| Indicator | MITQ | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 27.01 |
| Support Level | $0.72 | $0.24 |
| Resistance Level | $0.81 | $0.40 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 34.63 | 7.08 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.